SRZN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration...

Stats
Today's Volume	9 934.00
Average Volume	16 563.00
Market Cap	35.86M
EPS	$-4.41 ( 2024-05-08 )
Next earnings date	( $-4.25 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0.0450 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Li Yang	Buy	20 000	Option (right to buy)
2024-05-01	Williams Charles O	Buy	27 000	Option (right to buy)
2024-05-01	Parker Craig C	Buy	43 000	Option (right to buy)
2024-04-24	Li Yang	Buy	10 000	Option (right to buy)
2024-04-24	Li Yang	Buy	5 000	Restricted Stock Unit

INSIDER POWER
93.32
Last 99 transactions
Buy: 6 712 981 \| Sell: 808 309

Volume Correlation

Long: -0.23 (neutral)

Short: 0.06 (neutral)

Signal:(66.432) Neutral

Surrozen, Inc. Correlation

10 Most Positive Correlations
FULC	0.838
PXLW	0.832
KTCC	0.824
PTH	0.813
SGMO	0.81
RGTI	0.807
LKCO	0.804
NWS	0.804

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Surrozen, Inc. Correlation - Currency/Commodity

-0.41
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.31
( neutral )

Surrozen, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2023
Revenue:	$0
Gross Profit:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2022
Revenue:	$12.50M
Gross Profit:	$9.23M (73.85 %)
EPS:	$-11.95

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.556

Financial Reports:

No articles found.

Surrozen, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.